Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Times Somalia.
Press releases published on October 13, 2025
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …
Myseum Awarded Israeli Patent for Advanced Digital Privacy Technology
NEW BRUNSWICK, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Myseum, Inc. (Nasdaq: MYSE) (“Myseum” or the “Company”), a privacy-first social media and technology company, today announced that the Israel Patent Office has granted patent no. 290546 for the Company …
Third Millennium Unveils Multi-Technology Readers Combining Card and QR Code Access in One Device
Pontypool, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Third Millennium, a provider of access control solutions and part of HID, announces the launch of new RXQR and RXQRK readers — multi-technology access-control devices that integrate high-security RFID card and …
Auron Therapeutics to Participate in the 8th Annual Targeted Protein Degradation & Induced Proximity Summit
NEWTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that members of its leadership …
Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
Presentation will cover two-year clinical efficacy, immunogenicity and safety data Data will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing further insights into the clinical findings COPENHAGEN, …
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025
NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …
Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing
STOUGHTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management team will ring the Nasdaq opening bell on October 14, 2025 at 9:30 a.m. ET in celebration of its 10-year anniversary as a …
Hinge Bio Announces FDA Clearance of Investigational New Drug Application for HB2198, a Novel B cell-Depleting Agent, for Patients with Systemic Lupus Erythematosus and Lupus Nephritis
BURLINGAME, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a privately-held biotechnology company engaged in the discovery and development of innovative multi-specific medicines, announced the U.S. Food and Drug Administration (“FDA”) has …
HMNC Brain Health Presents New Analysis Supporting Rationale for Combining a Genetic Patient Selection Tool with a Vasopressin V1b Receptor Antagonist in the Treatment of Depression at ISCTM Conference in Amsterdam
MUNICH, Oct. 13, 2025 (GLOBE NEWSWIRE) -- HMNC Brain Health, a clinical-stage precision psychiatry biopharmaceutical company developing personalized treatments powered by predictive companion diagnostics, today announced it presented a retrospective …
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will be presenting late- …
MKS Inc. Announces Third Quarter 2025 Earnings Conference Call
ANDOVER, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- MKS Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that the Company will release third quarter 2025 financial results after market close on …
Nuvini Announces Open-Market Stock Purchases by Key Executives
~ Open Market Buys with Personal Funds~ NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Nuvini Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), a leading acquirer and operator of vertical market SaaS businesses in Latin America, today announced that …
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation
Cystic Fibrosis Foundation to provide up to $11 million in additional funding to accelerate development of 4D-710 for cystic fibrosis, following program and clinical data review by its independent scientific advisors Funding supports second 4D-710 dosing …
Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings
- VCN-01 expanded mPDAC data from VIRAGE Phase 2b trial to be presented at ESMO 2025 - - SYN-004 Interim blinded safety and pharmacokinetic data to be presented at IDWeek 2025 - Rockville, Md., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE …
Theriva™ Biologics anuncia próximas ponencias en congresos médicos
- Los datos ampliados del mPDAC del ensayo VIRAGE de fase 2b sobre el VCN-01 se presentarán en la ESMO 2025. - Los datos provisionales sobre seguridad y farmacocinética de SYN-004 se presentarán en IDWeek 2025. ROCKVILLE, Md., Oct. 13, 2025 (GLOBE NEWSWIRE …
Connect Appoints Tre Braquet as Chief Brand & Engagement Officer
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Connect, a premier nonprofit organization in San Diego’s innovation ecosystem dedicated to supporting entrepreneurs and cultivating thriving life science and technology communities, announced today that Tre …
Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors
REDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of biopharmaceutical …
Immutep Announces Successful Completion of FDA Project Optimus Requirements
Confirmation of 30mg efti as optimal biological dose relevant for Immutep’s oncology pipeline and potential future Biological License Applications (BLA) Registrational TACTI-004 (KEYNOTE-F91) Phase III trial in first line non-small cell lung cancer now in …
Apyx Medical Corporation Submits FDA 510(k) for Device Label Expansion of AYON Body Contouring System™ for Power Liposuction
Initiated Nationwide Commercial Launch of AYON in September The Company is Hosting a Virtual Key Opinion Leader Event to Discuss the Commercial Launch of AYON on October 14, 2025 CLEARWATER, Fla., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation …